Enbrel® is a soluble TNFR fusion protein1
Enbrel® is the only fully human soluble TNFR2
Enbrel® works like a naturally occurring soluble TNFR and inhibits TNF.2
*Mean half-life of approximately 4.3 days (70–100 hours)
†PASI 75 improvements were seen as early as 2 weeks with etanercept 25 mg BIW and 50 mg BIW5.
Disclaimer: The approved dose for Psoriasis is etanercept 25 mg BIW or 50 mg OW and 50 mg BIW can be used upto 12 weeks followed by 25 mg BIW/ 50 mg OW.
AS, ankylosing spondylitis; Fc, fragment crystallisable; IgG1, immunoglobulin G1; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis; QoL, quality of life; RA, rheumatoid arthritis; TNF, tumour necrosis factor; TNF-α, tumour necrosis factor alpha; TNFR, tumour necrosis factor receptor.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022